Skip to main content
NCBI home page
Japanese Journal of Cancer Research : Gann logoLink to Japanese Journal of Cancer Research : Gann
. 1998 Dec;89(12):1343–1351. doi: 10.1111/j.1349-7006.1998.tb00532.x

Schedule‐dependent and ‐independent Antitumor Activity of Paclitaxel‐based Combination Chemotherapy against M‐109 Murine Lung Carcinoma in vivo

Shuichi Fujimoto 1,✉, Hirotaka Chikazawa 2
PMCID: PMC5921735  PMID: 10081496

Abstract

The established antitumor efficacy of paclitaxel against a variety of human tumors has led to pre‐clinical and clinical studies to develop the paclitaxel‐based combination regimens. We examined in vivo the antitumor activity and toxicity of the combination of paclitaxel and each of 8 antitumor agents, currently in clinical use, against M‐109 murine lung carcinoma implanted subcutaneously into male CDF1 mice. Paclitaxel given intravenously at 24 mg/kg/day on a schedule of consecutive daily injections for 5 days (d1–5) induced reproducibly, in 6 experiments, a significant (37–82%) increase in the survival time of tumor‐bearing mice over saline‐treated control mice. Cisplatin at 4 and 2 mg/kg/day given intravenously on the same treatment schedule showed no significant antitumor activity when given alone; however, the combination of paclitaxel at 24 mg/kg/day (d1–5) followed by cisplatin at a dose of 2 mg/kg/day (d6–10) induced a significant (P<0.05) prolongation of the survival time of tumor‐bearing mice compared with the group given paclitaxel alone. On the other hand, treatment with these drugs on the reverse sequence caused toxic deaths of all mice. Such sequence‐dependent toxic death of mice was also observed with the combination of paclitaxel and carboplatin, etoposide or methotrexate. The combination of paclitaxel and adriamycin, cyclophosphamide, ranimustine or vinblastine (VLB) showed a sequence‐independent antitumor activity and a more‐than‐additive therapeutic effect was observed with the combination of paclitaxel and either VLB or ranimustine. Although the drug administration schedules used here may not be directly applicable to the clinic, knowledge of the nature of the sequence‐dependency in paclitaxel‐based combination chemotherapy should be useful in the design of clinical trials.

Keywords: Paclitaxel, Combination chemotherapy, Schedule dependency, M‐109 murine lung carcinoma, In vivo

Full Text

The Full Text of this article is available as a PDF (96.6 KB).

REFERENCES

  • 1. ) McGuire , W. P. , Rowinsky , E. K. , Rosenshein , N. B. , Grumbine , F. C. , Ettinger , D. S. , Armstrong , D. K. and Donehower , R. C.Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms . Ann. Intern. Med. , 111 , 273 – 279 ( 1989. ). [DOI] [PubMed] [Google Scholar]
  • 2. ) Holmes , F. A. , Walters , R. S. , Theriault , R. T. , Forman , A. D. , Newton , L. K. , Raber , M. N. , Buzdar , A. U. , Frye , D. K. and Hortobagyi , G. N.Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer . J. Natl. Cancer Inst. , 83 , 1797 – 1805 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 3. ) Murphy , W. K. , Fossella , F. V. , Winn , R. J. , Shin , D. M. , Hynes , H. E. , Gross , H. M. , Davilla , E. , Leimert , J. , Dhingra , H. , Raber , M. N. , Krakoff , I. H. and Hong , W. K.Phase II study of taxol in patients with untreated advanced non‐small‐cell lung cancer . J. Natl. Cancer Inst. , 85 , 384 – 388 ( 1993. ). [DOI] [PubMed] [Google Scholar]
  • 4. ) Rao , S. , Horwitz , S. B. and Ringel , I.Direct photoaffinity labeling of tubulin with taxol . J. Natl. Cancer Inst. , 84 , 785 – 787 ( 1992. ). [DOI] [PubMed] [Google Scholar]
  • 5. ) Schiff , P. B. , Fant , J. and Horwitz , S. B.Promotion of microtubule assembly in vitro by taxol . Nature , 277 , 665 – 667 ( 1979. ). [DOI] [PubMed] [Google Scholar]
  • 6. ) Madoc‐Jones , H. and Mauro , F.Interphase action of vinblastine and vincristine: differences in their lethal actions through the mitotic cycle of cultured mammalian cells . J. Cell Physiol. , 72 , 185 – 196 ( 1968. ). [DOI] [PubMed] [Google Scholar]
  • 7. ) Schiff , P. B. and Horwitz , S. B.Taxol stabilizes microtubules in mouse fibroblast cells . Proc. Natl. Acad. Sci. USA , 77 , 1561 – 1565 ( 1980. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. ) Milross , C. G. , Peters , L. J. , Hunter , N. R. , Mason , K. A. and Milas , L.Sequence‐dependent antitumor activity of paclitaxel (Taxol) and cisplatin in vivo . Int. J. Cancer , 62 , 599 – 604 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 9. ) Knick , V. C. , Eberwein , D. J. and Miller , C. G.Vinorelbine tartrate and paclitaxel combinations: enhanced activity against in vivo P388 murine leukemia cells . J. Natl. Cancer Inst. , 87 , 1072 – 1077 ( 1995. ). [DOI] [PubMed] [Google Scholar]
  • 10. ) Rose , W. C.Taxol: a review of its preclinical in vivo anti‐tumor activity . Anticancer Drugs , 3 , 311 – 321 ( 1992. ). [PubMed] [Google Scholar]
  • 11. ) Fujimoto , S.Schedule dependency of IV‐paclitaxel against SC‐M109 mouse lung cancer . Jpn. J. Cancer Chemother. , 21 , 671 – 677 ( 1994. ) ( in Japanese ). [PubMed] [Google Scholar]
  • 12. ) Corbett , T. H. , Griswold , D. P. , Jr. , Roberts , B. J. , Peckham , J. C. and Schabel , F. M. , Jr.Evaluation of single agents and combinations of chemotherapeutic agents in mouse colon carcinoma . Cancer , 40 , 2660 – 2680 ( 1977. ). [DOI] [PubMed] [Google Scholar]
  • 13. ) Geran , R. I. , Greenberg , N. R. , Macdonald , M. M. , Schumacher , A. M. and Abott , B. J.Protocols for screening chemical agents and natural products against animal tumors and other biological systems . Cancer Chemother. Rep. , Part 3 , 3 , 1 – 103 ( 1972. ). [Google Scholar]
  • 14. ) Speicher , L. A. , Barone , L. and Tew , K. D.Combined antimicrotubule activity of estramustine and taxol in human prostatic carcinoma cell lines . Cancer Res. , 52 , 4433 – 4440 ( 1992. ). [PubMed] [Google Scholar]
  • 15. ) Chou , T. C. , Motzer , R. J. , Tong , Y. and Bosl , G. J.Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design . J. Natl. Cancer Inst. , 86 , 1517 – 1524 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 16. ) Jordan , M. A. , Toso , R. J. , Thrower , D. and Wilson , L.Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations . Proc. Natl. Acad. Sci. USA , 90 , 9552 – 9556 ( 1993. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17. ) Kumar , N.Taxol‐induced polymerization of purified tubulin. Mechanism of action . J. Biol. Chem. , 256 , 10435 – 10441 ( 1981. ). [PubMed] [Google Scholar]
  • 18. ) Christen , R. D. , Jekunen , A. P. , Jones , J. A. , Thiebaut , F. , Shalinsky , D. R. and Howell , S. B.In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules . J. Clin. Invest. , 92 , 431 – 440 ( 1993. ). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19. ) Liebmann , J. E. , Fisher , J. , Teague , D. and Cook , J. A.Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells . Oncol. Res. , 6 , 25 – 31 ( 1994. ). [PubMed] [Google Scholar]
  • 20. ) Kubota , T. , Matsuzaki , S. W. , Hoshiya , Y. , Watanabe , M. , Kitajima , M. , Asanuma , F. , Yamada , Y. and Koh , J.Anti‐tumor activity of paclitaxel against human breast carcinoma xenografts serially transplanted into nude mice . J. Surg. Oncol. , 64 , 115 – 121 ( 1997. ). [DOI] [PubMed] [Google Scholar]
  • 21. ) Donaldson , K. L. , Goolsby , G. L. and Wahl , A. F.Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle . Int. J. Cancer , 57 , 847 – 855 ( 1994. ). [DOI] [PubMed] [Google Scholar]
  • 22. ) Rowinsky , E. K. , Gilbert , M. R. , McGuire , W. P. , Noe , D. A. , Grochow , L. B. , Forastiere , A. A. , Ettinger , D. S. , Lubejko , B. G. , Clark , B. , Sartorius , S. E. , Cornblath , D. R. , Hendricks , C. B. and Donehower , R. C.Sequences of taxol and cisplatin: a phase I and pharmacologic study . J. Clin. Oncol. , 9 , 1692 – 1703 ( 1991. ). [DOI] [PubMed] [Google Scholar]
  • 23. ) Skipper , H. E. , Schabel , F. M. , Jr. , Mellett , B. , Montgomery , J. A. , Wilkoff , L. J. , Lloyd , H. H. and Brockman , W. R.Implications of biochemical, cytokinetic, pharmacologic, and toxicologic relationships in the design of optimal therapeutic schedules . Cancer Chemother. Rep. , 54 , 431 – 450 ( 1970. ). [PubMed] [Google Scholar]
  • 24. ) Lawrence , T. S.Reduction of doxorubicin cytotoxicity by ouabain: correlation with topoisomerase‐induced DNA strand breakage in human and hamster cells . Cancer Res. , 48 , 725 – 730 ( 1988. ). [PubMed] [Google Scholar]
  • 25. ) Yang , L. , Rowe , T. C. and Liu , L. F.Identification of DNA topoisomerase II as an intracellular target of antitumor epipodophyllotoxins in simian virus 40‐infected monkey cells . Cancer Res. , 45 , 5872 – 5876 ( 1985. ). [PubMed] [Google Scholar]
  • 26. ) Hahn , S. M. , Liebmann , J. E. , Cook , J. , Fisher , J. , Goldspiel , B. , Venzon , D. , Mitchell , J. B. and Kaufmann , D.Taxol in combination with doxorubicin or etoposide. Possible antagonism in vitro . Cancer , 72 , 2705 – 2711 ( 1993. ). [DOI] [PubMed] [Google Scholar]

Articles from Japanese Journal of Cancer Research : Gann are provided here courtesy of Wiley

RESOURCES